| Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)
We write this article deep during the coronavirus pandemic gripping the UK. While we are not anywhere near through with this, it would appear that perhaps it is the end of the beginning (ABCD)
The Leader study has shown that the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (ABCD)
Not unexpectedly, diabetes has been identified as posing a particular adverse risk, along with chronic renal and coronary heart disease, and such surrogate risk indicators as obesity and hypertension (Practical Diabetes)
A position statement by Primary Care Diabetes Europe (Primary Care Diabetes)
The selection of diabetic patients for genetic testing is an ongoing challenge. Metabolic profiling, diabetes onset age, pancreatic antibodies, and C-peptide seem to be useful tools to better select patients for genetic testing (Diabetology & Metabolic Syndrome)
In DKD subjects, Linagliptin promotes an increase in CXCR4 expression on CD34 + progenitor cells with a concomitant improvement in vascular and renal parameters at 12 weeks (Cardiovascular Diabetology)
| 